PDCD1 and Miyoshi myopathy: Due to previous Food and Drug Administration alerts on safety concerns with increasing risk of death regarding combinations of anti‐PD‐1/PD‐L1 agents with immunomodulatory agents (i.e., pomalidomide, lenalidomide) in the treatment of MM,21 the protocol for this study implemented careful safety monitoring by a Data Monitoring Committee.